Evidence map›Paper›PMID 42890415›Full record

ArticleBiomedical optics express2026

Diffusion model with central annotation propagation for segmentation of ellipsoid zone maps on OCT scans of retinitis pigmentosa.

Kevin C Choy, Glenn J Jaffe, Sina Farsiu

Registry-linked trialAbstract read
In one paragraph

Article in Biomedical optics express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05537220 (NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05537220 phase3active not recruitingnot on this map

NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa

TypeinterventionalSponsorJohns Hopkins UniversityRan2023 to 2030Enrolled485ConditionsRetinitis PigmentosaArmsN-acetylcysteine, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kevin C ChoyBiomedical Engineering Department, Duke University, Durham, NC 27705, USA.ORCID https://orcid.org/0000-0002-4306-2549
Glenn J JaffeDepartment of Ophthalmology, Duke University School of Medicine, Durham, NC 27705, USA.
Sina FarsiuBiomedical Engineering Department, Duke University, Durham, NC 27705, USA.ORCID https://orcid.org/0000-0003-4872-2902

Funding

VISION RESEARCHP30EY005722 · NEI · DUKE UNIVERSITY · PI Vadim Y Arshavsky · 1985 to 2026
$19.3M
NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial with retinitis pigmentosa: OCT Reading CenterUG1EY033287 · NEI · DUKE UNIVERSITY · PI Sina Farsiu, GLENN JAFFE · 2022 to 2026
$1.3M
NEI NIH HHS P30 EY005722NEI NIH HHS UG1 EY033287
6 · The paper itself

Abstract

We present a fully automatic algorithm to segment the ellipsoid zone (EZ) on optical coherence tomography (OCT) images of retinitis pigmentosa (RP). We introduce Diffusion Projection U-Net (DPUN), a method to generate en face EZ maps from 3D OCT scans by leveraging diffusion models' state-of-the-art generative capabilities. We further propose Central Annotation Propagation (CAP), a semi-automatic approach that incorporates the segmentation of the central scan to segment all scans in a volume using a memory-reading paradigm. We demonstrated the effectiveness of our methods on a dataset consisting of 60 eyes from 60 participants enrolled in an international, multicenter, phase 3 RP clinical trial (NCT05537220) imaged with spectral-domain OCT at the baseline visit. DPUN outperformed all comparison methods for fully automatic segmentation. DPUN-CAP, which utilized central annotations, achieved the best performance of all models evaluated. The proposed methods produced measurements that were consistent with manual measurements of the EZ area, highlighting their potential utility for clinical trials in which EZ area is a key anatomic endpoint and for monitoring EZ loss progression and treatment response in clinical practice.

Identifiers

PMID42890415
PMCPMC13671693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.